Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 318

1.

Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.

Molife C, Bernauer MJ, Farr AM, Haynes VS, Kelsey D.

Postgrad Med. 2012 Sep;124(5):7-22. doi: 10.3810/pgm.2012.09.2586.

PMID:
23095422
2.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
3.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
4.

ADHD medication use, adherence, persistence and cost among Texas Medicaid children.

Barner JC, Khoza S, Oladapo A.

Curr Med Res Opin. 2011;27 Suppl 2:13-22. doi: 10.1185/03007995.2011.603303.

PMID:
21973228
5.

Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program.

Lawson KA, Johnsrud M, Hodgkins P, Sasané R, Crismon ML.

Clin Ther. 2012 Apr;34(4):944-956.e4. doi: 10.1016/j.clinthera.2012.02.021. Epub 2012 Mar 22.

PMID:
22444786
6.

Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.

Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

J Manag Care Pharm. 2007 Sep;13(7):561-9.

7.

A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.

Faraone SV, Glatt SJ.

J Clin Psychiatry. 2010 Jun;71(6):754-63. doi: 10.4088/JCP.08m04902pur. Epub 2009 Dec 29.

PMID:
20051220
8.

Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.

Lachaine J, Beauchemin C, Sasane R, Hodgkins PS.

Postgrad Med. 2012 May;124(3):139-48. doi: 10.3810/pgm.2012.05.2557.

PMID:
22691908
9.
10.

Pharmacotherapy with atomoxetine for US children and adolescents.

Bhatara VS, Aparasu RR.

Ann Clin Psychiatry. 2007 Jul-Sep;19(3):175-80.

PMID:
17729019
11.

Predictors of selecting atomoxetine therapy for children with attention-deficit-hyperactivity disorder.

Van Brunt DL, Johnston JA, Ye W, Pohl GM, Sun PJ, Sterling KL, Davis ME.

Pharmacotherapy. 2005 Nov;25(11):1541-9.

PMID:
16232017
12.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
13.

A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

Pohl GM, Van Brunt DL, Ye W, Stoops WW, Johnston JA.

BMC Health Serv Res. 2009 Jun 8;9:95. doi: 10.1186/1472-6963-9-95.

14.

Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder.

Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA.

Arch Pediatr Adolesc Med. 1999 Dec;153(12):1257-63.

PMID:
10591302
15.
16.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
17.

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.

Sasané R, Hodgkins P, Meijer W.

Curr Med Res Opin. 2010 Nov;26(11):2565-74. doi: 10.1185/03007995.2010.518131. Epub 2010 Sep 23.

PMID:
20863165
18.

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.

Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Oct;16(10):1203-15. doi: 10.3111/13696998.2013.832258. Epub 2013 Aug 23.

PMID:
23937642
19.

Psychotropic medication use in a population of children who have attention-deficit/hyperactivity disorder.

Guevara J, Lozano P, Wickizer T, Mell L, Gephart H.

Pediatrics. 2002 May;109(5):733-9.

PMID:
11986429
20.

Second opinions improve ADHD prescribing in a medicaid-insured community population.

Thompson JN, Varley CK, McClellan J, Hilt R, Lee T, Kwan AC, Lee T, Trupin E.

J Am Acad Child Adolesc Psychiatry. 2009 Jul;48(7):740-8. doi: 10.1097/CHI.0b013e3181a2b2ed.

PMID:
19465882

Supplemental Content

Support Center